A biomarker-guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP) trial design.

被引：0
|
作者：
Lo, Serigne N.
Gide, Tuba Nur
Gonzalez, Maria
Silva, Ines
Menzies, Alexander M.
Carlino, Matteo S.
Scolyer, Richard A.
Heritier, Stephane
Wilmott, James S.
Long, Georgina V.
机构：
[1] Univ Sydney, Fac Med & Hlth, Melanoma Inst Australia, Sydney, NSW, Australia
[2] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[3] Royal North Shore & Mater Hosp, Sydney, NSW, Australia
[4] Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[5] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp & NSW Hlth Pathol, Fac Med & Hlth,Charles Perkins Ctr, Sydney, NSW, Australia
[6] Monash Univ, Melbourne, Australia
[7] Univ Sydney, Melanoma Inst Australia, Royal North Shore & Mater Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9599
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
    Antoniou, Miranta
    Jorgensen, Andrea L.
    Kolamunnage-Dona, Ruwanthi
    [J]. PLOS ONE, 2016, 11 (02):
  • [2] A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials
    Mu, Rongji
    Pan, Haitao
    Xu, Guoying
    [J]. STATISTICS IN MEDICINE, 2021, 40 (02) : 382 - 402
  • [3] Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
    Antoniou, Miranta
    Kolamunnage-Dona, Ruwanthi
    Jorgensen, Andrea L.
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2017, 7 (01):
  • [4] A Bayesian Phase I/II Trial Design for Immunotherapy
    Liu, Suyu
    Guo, Beibei
    Yuan, Ying
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2018, 113 (523) : 1016 - 1027
  • [5] OPTIM-ARTS-An Adaptive Phase II Open Platform Trial Design With Application to a Metastatic Melanoma Study
    Racine-Poon, Amy
    D'Amelio, Anthony, Jr.
    Sverdlov, Oleksandr
    Haas, Tomas
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2022, 14 (03): : 283 - 294
  • [6] Development of a Bayesian response-adaptive trial design for the Dexamethasone for Excessive Menstruation study
    Hansen, Christian Holm
    Warner, Pamela
    Parker, Richard A.
    Walker, Brian R.
    Critchley, Hilary O. D.
    Weir, Christopher J.
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2017, 26 (06) : 2681 - 2699
  • [7] Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review (vol 7, 1, 2017)
    Antoniou, Miranta
    Kolamunnage-Dona, Ruwanthi
    Jorgensen, Andrea L.
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2018, 8 (02):
  • [8] A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial
    Yuan, Ying
    Huang, Xuelin
    Liu, Suyu
    [J]. STATISTICS IN MEDICINE, 2011, 30 (11) : 1218 - 1229
  • [9] Bayesian two-stage sequential enrichment design for biomarker-guided phase II trials for anticancer therapies
    Su, Liwen
    Chen, Xin
    Zhang, Jingyi
    Gao, Jun
    Yan, Fangrong
    [J]. BIOMETRICAL JOURNAL, 2022, 64 (07) : 1192 - 1206
  • [10] Phase II trial design with Bayesian adaptive randomization and predictive probability
    Yin, Guosheng
    Chen, Nan
    Lee, J. Jack
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2012, 61 : 219 - 235
12345